AMRX:NYE-Amneal Pharmaceuticals Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NYE

Last Closing Price

USD 4.95

Change

-0.10 (-1.98)%

Market Cap

USD 0.75B

Volume

0.68M

Avg Analyst Target

USD 8.00 (+61.62%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey. Address: 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-20 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ZTS Zoetis Inc

+0.13 (+0.07%)

USD94.34B 49.76 32.42
TAK Takeda Pharmaceutical Company ..

-0.09 (-0.52%)

USD54.18B 13.71 0.08
CTLT Catalent Inc

-0.17 (-0.12%)

USD23.26B 43.78 23.26
ELAN Elanco Animal Health Incorpora..

-0.57 (-1.76%)

USD15.33B 144.89 183.31
RDY Dr. Reddy's Laboratories Limit..

-1.32 (-1.99%)

USD11.02B 47.33 0.29
TEVA Teva Pharmaceutical Industries..

-0.30 (-3.34%)

USD10.26B 872.00 16.02
BHC Bausch Health Companies Inc

-1.16 (-4.25%)

USD9.77B 5.11 20.71
PRGO Perrigo Company plc

-0.58 (-1.32%)

USD5.88B 24.33 71.54
EBS Emergent BioSolutions Inc

-0.78 (-1.37%)

USD3.07B 10.38 6.28
TARO Taro Pharmaceutical Industries..

-1.33 (-2.05%)

USD2.46B 83.98 10.99

ETFs Containing AMRX

Symbol Name Weight Mer Price(Change) Market Cap
LOPX Direxion Low Priced Stock.. 0.00 % 0.50 %

-0.40 (-4.18%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.32% 67% D+ 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.32% 67% D+ 46% F
Trailing 12 Months  
Capital Gain 16.75% 60% D- 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.75% 60% D- 35% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -11.58% 20% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.58% 20% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 48.75% 33% F 19% F
Risk Adjusted Return -23.76% 33% F 6% F
Market Capitalization 0.75B 33% F 46% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 81.45 38% F 9% F
Price/Book Ratio 2.18 40% F 44% F
Price / Cash Flow Ratio 1.99 60% D- 74% C
EV/EBITDA 8.68 77% C+ 67% D+
Management Effectiveness  
Return on Equity 4.50% 67% D+ 36% F
Return on Invested Capital 6.97% 53% F 65% D
Return on Assets 2.83% 53% F 53% F
Debt to Equity Ratio 792.99% 15% F 4% F
Technical Ratios  
Short Ratio 3.23 60% D- 41% F
Short Percent 4.65% 33% F 41% F
Beta 1.28 33% F 36% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.